Seven-year follow-up data demonstrated favorable clinical outcomes and patient satisfaction for Medtronic’s 2-level Prestige LP™ Cervical Disc vs. 2-level anterior cervical discectomy and fusion (ACDF).
The randomized, controlled, investigational device exemption trial included 397 subjects.
Key findings from statistical analysis at seven years show that 2-level Prestige LP Disc patients exhibited:
Greater rates in overall success (78.6%) vs. 2-level ACDF (62.7%)
Greater rates in neurological success (91.6%) vs. 2-level ACDF (82.1%)
Greater success rates in patient-reported outcomes, including Neck Disability Index (87.0%), vs. 2-level ACDF (75.6%)
Lower rates of second surgeries (4.2%) at index levels vs. 2-level ACDF (14.7%)
Similar adverse event profiles to 2-level ACDF
Prestige LP is pending FDA premarket approval for 2-level use, and is the third cervical disc in Medtronic’s portfolio, alongside BRYAN and Prestige ST.
Presently, LDR’s Mobi-C is the only cervical disc approved for 2-level cervical disc replacement in the U.S.
Sources: Medtronic plc, ORTHOWORLD Inc.
Seven-year follow-up data demonstrated favorable clinical outcomes and patient satisfaction for Medtronic's 2-level Prestige LP™ Cervical Disc vs. 2-level anterior cervical discectomy and fusion (ACDF).
The randomized, controlled, investigational device exemption trial included 397 subjects.
Key findings from statistical analysis at seven...
Seven-year follow-up data demonstrated favorable clinical outcomes and patient satisfaction for Medtronic’s 2-level Prestige LP™ Cervical Disc vs. 2-level anterior cervical discectomy and fusion (ACDF).
The randomized, controlled, investigational device exemption trial included 397 subjects.
Key findings from statistical analysis at seven years show that 2-level Prestige LP Disc patients exhibited:
Greater rates in overall success (78.6%) vs. 2-level ACDF (62.7%)
Greater rates in neurological success (91.6%) vs. 2-level ACDF (82.1%)
Greater success rates in patient-reported outcomes, including Neck Disability Index (87.0%), vs. 2-level ACDF (75.6%)
Lower rates of second surgeries (4.2%) at index levels vs. 2-level ACDF (14.7%)
Similar adverse event profiles to 2-level ACDF
Prestige LP is pending FDA premarket approval for 2-level use, and is the third cervical disc in Medtronic’s portfolio, alongside BRYAN and Prestige ST.
Presently, LDR’s Mobi-C is the only cervical disc approved for 2-level cervical disc replacement in the U.S.
Sources: Medtronic plc, ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
